Shikonin derivative DMAKO-05 inhibits akt signal activation and melanoma proliferation

Chemical Biology and Drug Design

Volumn 87, Issue 6, 2016, Pages 895-904

  Yang, Yao Yao ^a   He, Hui Qiong ^a   Cui, Jia Hua ^a   Nie, Yun Juan ^a   Wu, Ya Xian ^a   Wang, Rui ^b   Wang, Gang ^c   Zheng, Jun Nian ^c   Ye, Richard D ^a   Wu, Qiong ^b   Li, Shao Shun ^a   Qian, Feng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b BENGBU MEDICAL COLLEGE   (China)

^c XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

apoptosis; cell cycle arrest; cytotoxicity; DMAKO 05; melanoma cell B16F0; shikonin

Indexed keywords

5 [ 1 [ 5,8 BIS(HYDROXYIMINO) 1,4 DIMETHOXY 5,8 DIHYDRONAPHTHALEN 2 YL] 4 METHYLPENT 3 ENYL 3 METHYLBUTANOIC ACID]; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SHIKONIN DERIVATIVE; UNCLASSIFIED DRUG; NAPHTHOQUINONE; SHIKONIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ATTENUATION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; G1 PHASE CELL CYCLE CHECKPOINT; IC50; IN VITRO STUDY; MELANOMA CELL; MELANOMA CELL LINE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; MELANOMA; METABOLISM; RAT; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; MELANOMA; NAPHTHOQUINONES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; SIGNAL TRANSDUCTION;

EID: 84959440928     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12722     Document Type: Article

References (42)

1. Rudolf K., Cervinka M., Rudolf E. (2014) Sulforaphaneinduced apoptosis involves p53 and p38 in melanoma cells. Apoptosis;19:734-747.
2. Besaratinia A., Tommasi S. (2014) Epigenetics of human melanoma: promises and challenges. J Mol Cell Biol;6:356-367.
3. Sun W., Schuchter L.M. (2001) Metastatic melanoma. Curr Treat Options Oncol;2:193-202.
4. Miller M.G., Rodgers A., Cohen G.M. (1986) Mechanisms of toxicity of naphthoquinones to isolated hepatocytes. Biochem Pharmacol;35:1177-1184.
5. Wang R.B., Zhou W., Meng Q.Q., Zhang X., Ding J., Xu Y., Song H.L., Yang K., Cui J.H., Li S.S. (2014) Design, synthesis, and biological evaluation of shikonin and alkannin derivatives as potential anticancer agents via a prodrug approach. ChemMedChem;9:2798-2808.
6. Zhang X., Wang R.B., Zhou W., Xiao S., Meng Q.Q., Li S.S. (2015) Antitumor activity of DMAKO-05, a novel shikonin derivative, and its metabolism in rat liver microsome. AAPS Pharm Sci Tech;16:259-266.
7. Wang R., Yin R., Zhou W., Xu D., Li S. (2012) Shikonin and its derivatives: a patent review. Expert Opin Ther Pat;22:977-997.
8. Chudnovsky Y., Khavari P.A., Adams A.E. (2005) Melanoma genetics and the development of rational therapeutics. J Clin Invest;115:813-824.
9. Davies M.A., Stemke-Hale K., Lin E., Tellez C., Deng W., Gopal Y.N., Woodman S.E., Calderone T.C., Ju Z., Lazar A.J., Prieto V.G., Aldape K., Mills G.B., Gershenwald J.E. (2009) Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin Cancer Res;15:7538-7546.
10. Madhunapantula S.V., Robertson G.P. (2009) The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res;22:400-419.
11. Wang J., Yang Z., Wen J., Ma F., Wang F., Yu K., Tang M., Wu W., Dong Y., Cheng X., Nie C., Chen L. (2014) SKLB-M8 induces apoptosis through the AKT/mTOR signaling pathway in melanoma models and inhibits angiogenesis with decrease of ERK1/2 phosphorylation. J Pharmacol Sci;126:198-207.
12. Howitt J., Low L.H., Putz U., Doan A., Lackovic J., Goh C.P., Gunnersen J., Silke J., Tan S.S. (2015) Ndfip1 represses cell proliferation by controlling Pten localization and signaling specificity. J Mol Cell Biol;7:119-131.
13. Shalini S., Dorstyn L., Dawar S., Kumar S. (2015) Old, new and emerging functions of caspases. Cell Death Differ;22:526-539.
14. Reinhardt H.C., Aslanian A.S., Lees J.A., Yaffe M.B. (2007) p53-deficient cells rely on ATM-and ATRmediated checkpoint signaling through the p38MAPK/ MK2 pathway for survival after DNA damage. Cancer Cell;11:175-189.
15. Manke I.A., Nguyen A., Lim D., Stewart M.Q., Elia A.E., Yaffe M.B. (2005) MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol Cell;17:37-48.
16. Garcia-Guerra L., Vila-Bedmar R., Carrasco-Rando M., Cruces-Sande M., Martin M., Ruiz-Gomez A., Ruiz-Gomez M., Lorenzo M., Fernandez-Veledo S., Mayor F. Jr, Murga C., Nieto-Vazquez I. (2014) Skeletal muscle myogenesis is regulated by G protein-coupled receptor kinase 2. J Mol Cell Biol;6:299-311.
17. Martins R., Lithgow G.J., Link W. (2015) Long live FOXO: unraveling the role of FOXO proteins in aging and longevity. Aging Cell; doi: 10.1111/acel.12427.
18. Huang H., Tindall D.J. (2007) Dynamic FoxO transcription factors. J Cell Sci;120(Pt 15):2479-2487.
19. Kloet D.E., Burgering B.M. (2011) The PKB/FOXO switch in aging and cancer. Biochim Biophys Acta;1813:1926-1937.
20. Svendsen A.M., Winge S.B., Zimmermann M., Lindvig A.B., Warzecha C.B., Sajid W., Horne M.C., De Meyts P. (2014) Down-regulation of cyclin G2 by insulin, IGF-I (insulin-like growth factor 1) and X10 (AspB10 insulin): role in mitogenesis. Biochem J;457:69-77.
21. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature;378:785-789.
22. Ding Q., He X., Xia W., Hsu J.M., Chen C.T., Li L.Y., Lee D.F., Yang J.Y., Xie X., Liu J.C., Hung M.C. (2007) Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res;67:4564-4571.
23. Farago M., Dominguez I., Landesman-Bollag E., Xu X., Rosner A., Cardiff R.D., Seldin D.C. (2005) Kinaseinactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. Cancer Res;65:5792-5801.
24. Sakamaki J., Daitoku H., Kaneko Y., Hagiwara A., Ueno K., Fukamizu A. (2012) GSK3beta regulates gluconeogenic gene expression through HNF4alpha and FOXO1. J Recept Signal Transduct Res;32:96-101.
25. Huo X., Liu S., Shao T., Hua H., Kong Q., Wang J., Luo T., Jiang Y. (2014) GSK3 protein positively regulates type I insulin-like growth factor receptor through forkhead transcription factors FOXO1/3/4. J Biol Chem;289:24759-24770.
26. Esakky P., Hansen D.A., Drury A.M., Moley K.H. (2015) Cigarette smoke-induced cell cycle arrest in spermatocytes [GC-2spd(ts)] is mediated through crosstalk between Ahr-Nrf2 pathway and MAPK signaling. J Mol Cell Biol;7:73-87.
27. Qian F., Deng J., Lee Y.G., Zhu J., Karpurapu M., Chung S., Zheng J.N., Xiao L., Park G.Y., Christman J.W. (2015) The transcription factor PU.1 promotes alternative macrophage polarization and asthmatic airway inflammation. J Mol Cell Biol;7:557-567.
28. Madhunapantula S.V., Robertson G.P. (2012) Chemoprevention of melanoma. Adv Pharmacol;65:361-398.
29. Ascierto M.L., Melero I., Ascierto P.A. (2015) Melanoma: from incurable beast to a curable bet. The success of immunotherapy. Front Oncol;5:152.
30. Tsao H., Atkins M.B., Sober A.J. (2004) Management of cutaneous melanoma. N Engl J Med;351:998-1012.
31. Zhang D., Tang B., Xie X., Xiao Y.F., Yang S.M., Zhang J.W. (2015) The interplay between DNA repair and autophagy in cancer therapy. Cancer Biol Ther;16:1005-1013.
32. Feng Y.M., Feng C.W., Chen S.Y., Hsieh H.Y., Chen Y.H., Hsu C.D. (2015) Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase. BMC Cancer; 15:134.
33. Lin D.W., Chung B.P., Kaiser P. (2014) S-adenosylmethionine limitation induces p38 mitogen-activated protein kinase and triggers cell cycle arrest in G1. J Cell Sci;127(Pt 1):50-59.
34. Safarzadeh E., Sandoghchian Shotorbani S., Baradaran B. (2014) Herbal medicine as inducers of apoptosis in cancer treatment. Adv Pharm Bull;4(Suppl. 1):421-427.
35. Dias N., Bailly C. (2005) Drugs targeting mitochondrial functions to control tumor cell growth. Biochem Pharmacol; 70:1-12.
36. Khan N., Adhami V.M., Mukhtar H. (2008) Apoptosis by dietary agents for prevention and treatment of cancer. Biochem Pharmacol;76:1333-1339.
37. Zhao H.F., Wang J., Tony To S.S. (2015) The phosphatidylinositol 3-kinase/Akt and c-Jun N-terminal kinase signaling in cancer: alliance or contradiction? (Review). Int J Oncol;47:429-436.
38. Petrulea M.S., Plantinga T.S., Smit J.W., Georgescu C.E., Netea-Maier R.T. (2015) PI3K/Akt/mTOR: a promising therapeutic target for non-medullary thyroid carcinoma. Cancer Treat Rev;41:707-713.
39. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., Velculescu V.E. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science;304:554.
40. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., et al. (2007) Temsirolimus, interferon alfa, or both for advanced renalcell carcinoma. N Engl J Med;356:2271-2281.
41. Johnson D.B., Puzanov I. (2015) Treatment of NRASmutant melanoma. Curr Treat Options Oncol;16:15.
42. Cappellini A., Tabellini G., Zweyer M., Bortul R., Tazzari P.L., Billi A.M., Fala F., Cocco L., Martelli A.M. (2003) The phosphoinositide 3-kinase//Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27Kip1 and control of cyclin D1 expression. Leukemia;17:2157-2167.